Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDTPT for HFpEF and Diabetes Mellitus
NCT04697485Phase 4Withdrawn
- Sponsor
- Northwestern University
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of bumetanide, eplerenone, dapagliflozin in heart failure with preserved ejection fraction (HFpEF), type 2 diabetes mellitus (T2DM), sponsored by Northwestern University. Planned start Jan 2021; status: withdrawn.
02
Drugs
bumetanideeplerenonedapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04697485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697485.